AKT1 and neoplasm: Treatment with TAE226, a dual inhibitor of IGF-1R and focal adhesion kinase (FAK), significantly suppressed proliferation and tumor growth of ES cells in vivo and in vitro by inducing apoptosis by inhibiting IGF-1R, FAK, and AKT activation when compared with PF-562,271, a dual inhibitor of FAK and proline-rich tyrosine kinase 2 (Pyk2).